Similarly, VEGF targeting which theoretically represents another attractive way of normalizing tumor vasculature and overcoming hypoxia, failed to improve OS in GBM patients where VEGF targeting was particularly alluring given its centrality to the disease pathogenesis (250–252). This evidence concerns the gene VEGFA and glioblastoma.